Introduction {#Sec1}
============

The aim of the present study was to cross-culturally adapt and validate the Brazilian Portuguese parent, child/adult version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) \[[@CR1]\] in patients with juvenile idiopathic arthritis (JIA). The JAMAR assesses the most relevant parent/patient reported outcomes in JIA, including overall well-being, functional status, health related quality of life (HRQoL), pain, morning stiffness, disease activity/status/course, articular and extra-articular involvement, drug-related side effects/compliance and satisfaction with illness outcome.

This project was part of a larger multinational study conducted by the Paediatric Rheumatology International Trials Organisation (PRINTO) \[[@CR2]\] aimed to evaluate the Epidemiology, Outcome and Treatment of Childhood Arthritis (EPOCA) in different geographic areas \[[@CR3]\].

We report herein the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Brazilian Portuguese language.

Materials and methods {#Sec2}
=====================

The methodology employed has been described in detail in the introductory paper of the supplement \[[@CR4]\]. In brief, it was a cross-sectional study of JIA children, classified according to the ILAR criteria \[[@CR5], [@CR6]\] and enrolled from May 2012 to May 2015. Children were recruited after Ethics Committee approval and consent from at least one parent.

The JAMAR {#Sec3}
---------

The JAMAR \[[@CR1]\] includes the following 15 sections:

Assessment of physical function (PF) using 15-items in which the ability of the child to perform each task is scored as follows: 0 = without difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do and not applicable if it was not possible to answer the question or the patient was unable to perform the task due to their young age or to reasons other than JIA. The total PF score ranges from 0 to 45 and has three components: PF-lower limbs (PF-LL); PF-hand and wrist (PF-HW) and PF-upper segment (PF-US) each scoring from 0 to 15 \[[@CR7]\]. Higher scores indicating higher degree of disability \[[@CR8]--[@CR10]\];rating of the intensity of the patient's pain on a 21-numbered circle visual analogue scale (VAS) \[[@CR11]\];assessment of the presence of joint pain or swelling (present/absent for each joint);assessment of morning stiffness (present/absent);assessment of extra-articular symptoms (fever and rash) (present/absent);rating of the level of disease activity on a 21-circle VAS;rating of disease status at the time of the visit (categorical scale);rating of disease course from previous visit (categorical scale);checklist of the medications the patient is taking (list of choices);checklist of side effects of medications;report of difficulties with medication administration (list of items);report of school/university/work problems caused by the disease (list of items);assessment of HRQoL, through the Physical Health (PhH), and Psychosocial Health (PsH) subscales (five items each) and a total score.The four-point Likert response, referring to the prior month, are 'never' (score = 0), 'sometimes' (score = 1), 'most of the time' (score = 2) and 'all the time' (score = 3). A 'not applicable' column was included in the parent version of the questionnaire to designate questions that cannot be answered because of developmental immaturity. The total HRQoL score ranges from 0 to 30, with higher scores indicating worse HRQoL. A separate score for PhH and PsH (range 0--15) can be calculated \[[@CR12]--[@CR14]\];rating of the patient's overall well-being on a 21-numbered circle VAS;a question about satisfaction with the outcome of the illness (Yes/No) \[[@CR15]\].

The JAMAR is available in three versions, one for parent proxy-report (child's age 2--18), one for child self-report, with the suggested age range of 7--18 years, and one for adults.

Cross cultural adaptation and validation {#Sec4}
----------------------------------------

The process of cross-cultural adaptation was conducted according to international guidelines with 2--3 forward and backward translations. In those countries for which the translation of JAMAR had been already cross-cultural adapted in a similar language (i.e. Spanish in South American countries), only the probe technique was performed. Reading comprehension and understanding of the translated questionnaires were tested in a probe sample of at least ten JIA parents and ten patients.

Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents.

The statistical validation phase explored the descriptive statistics and the psychometric issues \[[@CR16]\]. In particular, we evaluated the following validity components: the first Likert assumption \[mean and standard deviation (SD) equivalence\]; the second Likert assumption or equal items-scale correlations (Pearson *r*: all items within a scale should contribute equally to the total score); third Likert assumption (item internal consistency or linearity for which each item of a scale should be linearly related to the total score that is 90% of the items should have Pearson *r* ≥ 0.4); floor/ceiling effects (frequency of items at lower and higher extremes of the scales, respectively); internal consistency, measured by the Cronbach's alpha, interscale correlation (the correlation between two scales should be lower than their reliability coefficients, as measured by Cronbach's alpha); test--retest reliability or intra-class correlation coefficient (reproducibility of the JAMAR repeated after 1 or 2 weeks); and construct validity in its two components: the convergent or external validity which examines the correlation of the JAMAR sub-scales with the 6 JIA core set variables, with the addition of the parent assessment of disease activity and pain by the Spearman's correlation coefficients (*r*) \[[@CR17]\] and the discriminant validity, which assesses whether the JAMAR discriminates between the different JIA categories and healthy children \[[@CR18]\].

Quantitative data were reported as medians with first and third quartiles and categorical data as absolute frequencies and percentages.

The complete Brazilian Portuguese parent and patient versions of the JAMAR are available upon request to PRINTO.

Results {#Sec5}
=======

Cross cultural adaptation {#Sec6}
-------------------------

The Brazilian Portuguese JAMAR was cross-culturally adapted from the British English version with three forward and two backward translations with a concordance for 115/123 (93.5%) translations lines for the parent version and 116/120 (96.7%) lines for the child version.

In the probe technique analysis, 120/123 (97.6%) lines of the parent version of the JAMAR were understood by at least 80% of the 10 parents tested (median 100%; range 70--100%) and 117/120 (97.5%) lines of the patient version of the JAMAR were understood by at least 80% of the children (median 100%; range 70--100%). Lines 52, 53, and 77 of the parent version of the JAMAR and lines 50, 51, and 75 were modified according to parents' and patients' suggestions, respectively.

Demographic and clinical characteristics of the subjects {#Sec7}
--------------------------------------------------------

A total of 231 JIA patients and 72 healthy children (total of 303 subjects), were enrolled at three paediatric rheumatology centres. In the 231 JIA subjects, the JIA categories were 14.7% systemic arthritis, 43.3% oligoarthritis, 22.5% RF negative polyarthritis, 4.8% RF positive polyarthritis, 1.7% psoriatic arthritis, 10.8% enthesitis related arthritis and 2.2% undifferentiated arthritis (Table [1](#Tab1){ref-type="table"}).

Table 1Descriptive statistics (medians first third quartiles or absolute frequencies and %) for the 231 JIA patientsSystemicOligoarthritisRF − poly-arthritisRF + poly-arthritisPsoriatic arthritisEnthesitis related arthritisUndifferentiated arthritisAll JIA patientsHealthy*N* = 34*N* = 100*N* = 52*N* = 11*N* = 4*N* = 25*N* = 5*N* = 231*N* = 72Female18 (52.9%)72 (72%)36 (69.2%)8 (72.7%)3 (75%)2 (8%)2 (40%)141 (61%)^\#^45 (62.5%)Age at visit13.5 (10.3--16.5)12 (9.1--15)11.5 (8.7--14.6)14.6 (12.8--17.3)13.2 (11.6--14.7)14.7 (12.6--17.1)8.9 (7--13.9)13.1 (9.8--15.3)\*12.1 (9.4--14.6)Age at onset7.6 (4.3--11.6)5.5 (2.7--9.7)5.3 (2.6--9.1)8.9 (6.9--12.6)8.4 (6.9--10.8)8.7 (6--9.9)6.6 (3.7--6.7)6.4 (3--9.8)\*Disease duration3.4 (1.4--7.7)4.9 (2.3--7.9)4.5 (1.7--8.6)4.7 (2.2--7.6)4.7 (2.3--6.3)5.3 (4.1--9.2)3.2 (2.1--3.3)4.7 (2.1--8.1)ESR13 (8--33)9 (4--23)14 (6--23)22.5 (15--40)11 (6--15)10 (4--20)10 (7--13)11 (5--23)MD VAS (0--10 cm)0 (0--4)0 (0--1)1 (0--4)4 (1.5--7)0 (0--2)0 (0--2)0 (0--0)0 (0--2)\*No. swollen joints0 (0--2)0 (0--1)1 (0--4)2 (0--7)1 (0--3)0 (0--2)0 (0--0)0 (0--2)\*No. joints with pain0 (0--2)0 (0--0)1 (0--3)1 (0--5)0 (0--1)0 (0--0)0 (0--0)0 (0--1)^\#^No. joints with LOM0 (0--5)0 (0--0)1 (0--7)4 (2--20)0.5 (0--2.5)0 (0--1)0 (0--0)0 (0--2)^\#^No. active joints0 (0--2)0 (0--1)2 (0--4.5)4 (1--7)1 (0--3)0 (0--2)0 (0--0)0 (0--2)^\#^Active systemic features3 (8.8%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)3 (1.3%)\*ANA status1 (2.9%)20 (20%)7 (13.5%)1 (9.1%)0 (0%)0 (0%)1 (20%)30 (13%)Uveitis1 (2.9%)15/99 (15.2%)2 (3.8%)0 (0%)0 (0%)1 (4%)0 (0%)19/229 (8.3%)PF Total Score2 (0--7)0 (0--3)2 (0--5)6 (0--12)1.5 (0.5--2.5)0 (0--3)1 (0--1)1 (0--4)0 (0--0)^\#^Pain VAS0.3 (0--4)0 (0--1.3)1 (0--2.5)0.5 (0--3.5)0 (0--0.5)0 (0--4)0 (0--0)0 (0--2)0 (0--0)^\#^Disease Activity VAS0 (0--4.5)0 (0--1)1 (0--5)1.5 (0--3.5)0.5 (0--1)0 (0--4)0 (0--0)0 (0--3)Well-being VAS0 (0--4)0 (0--1.3)0.5 (0--2)2 (0--7.5)0.3 (0--1)0 (0--4.5)0 (0--0)0 (0--2)HRQoL PhH1.5 (0--5)1 (0--2)1 (0--4)3 (0--6)0 (0--0.5)1 (0--4)0 (0--0)1 (0--3)0 (0--0)^\#^HRQoL PsH1 (0--4)1 (0--3)1 (0--4)2 (0--3)5 (2--6.5)1 (0--3)1 (1--2)1 (0--3)0 (0--1)\*\*HRQoL Total Score3.5 (0--10)2 (0--5)3 (1--7)3 (1--11)5 (2--7)3 (0--6)1 (1--3)3 (0--6)0 (0--2)^\#^Pain/swell. in \> 1 joint16 (47.1%)31/96 (32.3%)31/51 (60.8%)8 (72.7%)0 (0%)10 (40%)0 (0%)96/226 (42.5%)5/70 (7.1%)^\#^Morning stiff. \> 15 min6 (17.6%)7/96 (7.3%)9/51 (17.6%)2 (18.2%)0 (0%)3 (12%)0 (0%)27/226 (11.9%)0 (0%)\*Subjective remission13 (38.2%)29/96 (30.2%)29/51 (56.9%)8 (72.7%)1 (25%)11 (44%)0 (0%)91/226 (40.3%)In treatment23 (67.6%)56/96 (58.3%)44/51 (86.3%)10 (90.9%)3 (75%)19 (76%)3 (60%)158/226 (69.9%)Reporting side effects8/23 (34.8%)10/56 (17.9%)12/44 (27.3%)0 (0%)1/3 (33.3%)1/19 (5.3%)1/3 (33.3%)33/158 (20.9%)Taking medication regularly23/23 (100%)52/56 (92.9%)40/44 (90.9%)9/10 (90%)3/3 (100%)16/19 (84.2%)3/3 (100%)146/158 (92.4%)With problems attending school2/19 (10.5%)5/77 (6.5%)1/34 (2.9%)0 (0%)0 (0%)2/18 (11.1%)1 (20%)11/163 (6.7%)0 (0%)\*Satisfied with disease outcome27 (79.4%)83/96 (86.5%)42/51 (82.4%)7 (63.6%)3 (75%)22 (88%)5 (100%)189/226 (83.6%)Data related to the JAMAR refers to the 226 JIA patients and to the 70 healthy subjects for whom the questionnaire has been completed by the parents*JAMAR* Juvenile Arthritis Multidimensional Assessment Report, *ESR* erythrocyte sedimentation rate, *MD* Medical Doctor, *VAS* visual analogue scale (score 0--10; 0 = no activity, 10 = maximum activity), *LOM* limitation of motion, *ANA* Anti-nuclear antibodies, *PF* physical function (total score ranges from 0 to 45), *HRQoL* health related quality of life (total score ranges from 0 to 30), *PhH* Physical Health (total score ranges from 0 to 15), *PsH* psychosocial health (total score ranges from 0 to 15)*p* values refers to the comparison of the different JIA categories or to JIA versus healthy. \**p* \< 0.05, \*\**p* \< 0.001, ^\#^*p* \< 0.0001

A total of 296/303 (97.7%) subjects had the parent version of the JAMAR completed by a parent (226 from parents of JIA patients and 70 from parents of healthy children). The JAMAR was completed by 256/296 (86.5%) mothers and 40/296 (13.5%) fathers. The child version of the JAMAR was completed by 265/303 (87.5%) children age 6.0 years or older. Also patients younger than 7 years old, capable to assess their personal condition and able to read and write, were asked to fill in the patient version of the questionnaire.

Discriminant validity {#Sec8}
---------------------

The JAMAR results are presented in Table [1](#Tab1){ref-type="table"}, including the scores \[median (first--third quartile)\] obtained for the PF, the PhH, the PsH subscales and total score of the HRQoL scales. The JAMAR components discriminated well between healthy subjects and JIA patients.

In summary, the JAMAR revealed that JIA patients had a greater level of disability and pain, as well as a lower HRQoL than their healthy peers.

Psychometric issues {#Sec9}
-------------------

The main psychometric properties of both parent and child versions of the JAMAR are reported in Table [2](#Tab2){ref-type="table"}. The following "[Results](#Sec5){ref-type="sec"}" section, unless otherwise specified, refers mainly to the parent's version findings.

Table 2Main psychometric characteristics between the parent and child version of the JAMARParent *N* = 226/296Child *N* = 203/265Missing values (first--third quartiles)No missing valuesNo missing valuesResponse patternPF and HRQoL positively skewedPF and HRQoL positively skewedFloor effect, median PF87.2%90.1% HRQoL PhH72.6%75.9% HRQoL PsH66.8%70.0% Pain VAS57.5%53.2% Disease activity VAS51.3%48.3% Well-being VAS55.7%59.6%Ceiling effect, median PF0.9%0.5% HRQoL PhH4.0%2.0% HRQoL PsH3.1%3.4% Pain VAS1.8%1.5% Disease activity VAS0.4%1.5% Well-being VAS1.3%1.0%Items with equivalent item-scale correlation87% for PF, 80% for HRQoL93% for PF, 100% for HRQoLItems with items-scale correlation ≥ 0.4100% for PF, 100% for HRQoL93% for PF, 100% for HRQoLCronbach's alpha PF-LL0.890.86 PF-HW0.890.87 PF-US0.830.79 HRQoL-PhH0.850.83 HRQoL-PsH0.790.78Items with item-scale correlation lower than the Cronbach alpha100% for PF, 100% for HRQoL100% for PF, 100% for HRQoLTest--retest intraclass correlation PF total score0.940.95 HRQoL-PhH0.920.89 HRQoL-PsH0.870.81Spearman correlation with JIA core-set variables, median PF0.40.4 HRQoL PhH0.40.5 HRQoL PsH0.20.3 Pain VAS0.40.3 Disease activity VAS0.40.3 Well-being VAS0.40.4*JAMAR* Juvenile Arthritis Multidimensional Assessment Report, *JIA* juvenile idiopathic arthritis, *VAS* visual analogue scale, *PF* physical function, *HRQoL* health related quality of life, *PhH* physical health, *PsH* psychosocial health, *PF-LL* PF-lower limbs, *PF-HW* PF-hand and wrist, *PF-US* PF-upper segment

Descriptive statistics (first Likert assumption) {#Sec10}
------------------------------------------------

There were no missing results for all JAMAR items, since data were collected through a web-based system that did not allow to skip answers and input null values. The response pattern for both PF and HRQoL was positively skewed toward normal functional ability and normal HRQoL. All response choices were used for the different HRQoL items except for item 8, whereas a reduced number of response choices was used for PF item 15.

The mean and SD of the items within a scale were roughly equivalent for the PF and for the HRQoL items (data not shown). The median number of items marked as not applicable was 1% (0--1%) for the PF and 4% (3--6%) for the HRQoL.

Floor and ceiling effect {#Sec11}
------------------------

The median floor effect was 87.2% (80.5--88.5%) for the PF items, 72.6% (65.0--74.3%) for the HRQoL PhH items, and 66.8% (64.2--70.8%) for the HRQoL PsH items. The median ceiling effect was 0.9% (0.9--2.7%) for the PF items, 4.0% (2.7--4.0%) for the HRQoL PhH items, and 3.1% (2.2--3.5%) for the HRQoL PsH items. The median floor effect was 57.5% for the pain VAS, 51.3% for the disease activity VAS and 55.7% for the well-being VAS. The median ceiling effect was 1.8% for the pain VAS, 0.4% for the disease activity VAS and 1.3% for the well-being VAS.

Equal items-scale correlations (second Likert assumption) {#Sec12}
---------------------------------------------------------

Pearson items-scale correlations corrected for overlap were roughly equivalent for items within a scale for 87% of the PF items, with the exception of PF items 13 and 15, and for 80% of the HRQoL items, with the exception of items 8 and 9.

Items internal consistency (third Likert assumption) {#Sec13}
----------------------------------------------------

Pearson items-scale correlations were ≥ 0.4 for 100% of items of the PF and 100% of items of the HRQoL.

Cronbach's alpha internal consistency {#Sec14}
-------------------------------------

Cronbach's alpha was 0.89 for PF-LL, 0.89 for PF-HW, 0.83 for PF-US. Cronbach's alpha was 0.85 for HRQoL-PhH and 0.79 for HRQoL-PsH.

Interscale correlation {#Sec15}
----------------------

The Pearson correlation of each item of the PF and the HRQoL with all items included in the remaining scales of the questionnaires was lower than the Cronbach's alpha.

Test--retest reliability {#Sec16}
------------------------

Reliability was assessed in 15 JIA patients, by re-administering both versions (parent and child) of the JAMAR after a median of 7 days (7--10 days). The intraclass correlation coefficients (ICC) for the PF total score showed an almost perfect reproducibility (ICC 0.94). The ICC for the HRQoL PhH and for the HRQoL PsH showed an almost perfect reproducibility (ICC 0.92 and ICC 0.87, respectively).

Convergent validity {#Sec17}
-------------------

The Spearman correlation of the PF total score with the JIA core set of outcome variables ranged from 0.4 to 0.5 (median 0.4). The PF total score best correlation was observed with the parent assessment of pain (*r* = 0.6, *p* \< 0.001). For the HRQoL, the median correlation of the PhH with the JIA core set of outcome variables ranged from 0.4 to 0.6 (median 0.4), whereas for the PsH ranged from 0.2 to 0.4 (median 0.2). The PhH showed the best correlation with the parent's assessment of pain (*r* = 0.7, *p* \< 0.001) and the PsH with the parent global assessment of well-being (*r* = 0.4, *p* \< 0.001). The median correlations between the pain VAS, the well-being VAS, and the disease activity VAS and the physician-centered and laboratory measures were 0.4 (0.3--0.4), 0.4 (0.3--0.5), 0.4 (0.4--0.5), respectively.

Discussion {#Sec18}
==========

In this study, the Brazilian Portuguese version of the JAMAR was cross-culturally adapted from the original standard English version with 2 forward and 2 backward translations. According to the results of the validation analysis, the Brazilian Portuguese parent and patient versions of the JAMAR have satisfactory psychometric properties. The disease-specific components of the questionnaire discriminated well between patients with JIA and healthy controls. Psychometric performance was good for all the JAMAR domains and the overall internal consistency was equally good for all the domains.

In the external validity evaluation, the Spearman's correlations of the PF and HRQoL scores with JIA core set parameters were moderate.

The results obtained for the parent version of the JAMAR are very similar to those obtained for the child version, which suggests that children are equally reliable proxy reporters of their disease and health status as their parents.

The JAMAR is aimed to evaluate the side effects of medications and school attendance, which are other dimensions of daily life that were not previously considered by other HRQoL tools. This may provide useful information for intervention and follow-up in health care.

In conclusion, the Brazilian Portuguese version of the JAMAR was found to have satisfactory psychometric properties and it is, thus, a reliable and valid tool for the multidimensional assessment of children with JIA.

The local members of the Paediatric Rheumatology International Trials Organisation (PRINTO) participating in the project are listed in the dedicated tables no. 2 and 3 of \"10.1007/s00296-018-3944-1 / Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology".
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